Form 4: Amedisys CEO Richard Ashworth Awarded 58,316 Restricted Stock Units
SEC Form 4 Filing
Amedisys CEO Richard M. Ashworth received 58,316 time-based Restricted Stock Units (RSUs) on February 16, 2025, according to a Form 4 filing with the SEC.
Summary
- Richard M. Ashworth, President and CEO of Amedisys Inc., was granted 58,316 time-based Restricted Stock Units (RSUs) on February 16, 2025.
- Each RSU represents a contingent right to receive one share of Amedisys' common stock.
- The RSUs will vest 25% on each of February 16, 2026, and February 16, 2027, and 50% on February 16, 2028, contingent upon continuous employment with Amedisys.
- Following the transaction, Ashworth directly owns 159,925 shares of Amedisys common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, indicating confidence in the CEO's continued leadership and alignment with shareholder interests. There are no red flags or negative implications.
Positives
- The RSU grant aligns the CEO's interests with the long-term performance of the company, as the vesting is tied to continued employment and future dates.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.
Industry Context
Equity compensation, such as RSU grants, is a common practice in the healthcare industry to incentivize and retain top executives. These grants align executive compensation with company performance and shareholder value.
Comparison to Industry Standards
- RSU grants are a standard form of executive compensation in publicly traded companies, including healthcare providers like Amedisys.
- Companies such as LHC Group (now part of Optum) and Encompass Health also utilize similar equity-based compensation plans for their executives.
- The vesting schedules are typical, with vesting occurring over a period of 3-4 years to encourage long-term commitment.
Stakeholder Impact
- Shareholders: The RSU grant aligns the CEO's interests with the company's long-term performance, potentially benefiting shareholders.
- Employees: The grant can boost employee morale by demonstrating that leadership is invested in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/16/2025 | Date of the transaction: Grant of 58,316 RSUs to Richard M. Ashworth. |
| 02/16/2026 | First vesting date: 25% of the RSUs vest. |
| 02/16/2027 | Second vesting date: 25% of the RSUs vest. |
| 02/16/2028 | Final vesting date: 50% of the RSUs vest. |
| 02/19/2025 | Date of signature on the Form 4 filing. |
Keywords
Amedisys, Richard Ashworth, RSU, Restricted Stock Units, Form 4, SEC, Beneficial Ownership, Equity Compensation, CEO, AMED
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.